KYTH Key Stats
| Income Statement | |
| Revenue TTM | 19.69M |
| Revenue Quarterly YoY Growth | -100.0% |
| EPS Diluted TTM | |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -36.80M |
| Profitability | |
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 391.96M |
| Enterprise Value | 316.57M |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 5.688 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.0569 |
| Free Cash Flow | -15.67M |
| Return on Equity | |
KYTH News
- Nasdaq stocks posting largest percentage increases May 13
- Kythera Biophrm (KYTH) Posts Q1 Loss of 77c/Share Street Insider May 13
- KYTHERA Biopharmaceuticals Announces First Quarter 2013 Operating Results GlobeNewswire May 13
- KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Fin... May 13
- Q1 2013 Kythera Biopharmaceuticals Earnings Release - Time Not Supplied May 13
- KYTHERA Biopharmaceuticals to Present at Bank of America Merrill Lynch 2013 Heal... May 7
- KYTHERA Biopharmaceuticals to Release First Quarter 2013 Operating Results noodls May 2
- KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events Apr 25
- Bearish MACD for Kythera Biopharmaceuticals Inc. - Tale of the Tape Zacks Apr 24
- KYTHERA Biopharmaceuticals Presents Positive MRI Results from Phase IIb Study of... Apr 13
KYTH Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). KYTHERA Biopharmaceuticals is up 0.00% over the last year vs S&P 500 Total Return up 30.71%, Cyanotech Corporation down 29.51%, and Intercept Pharmaceuticals up 0.00%.
KYTH Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these KYTH related companies
Pro Ratings for KYTH
Pro Report PDF for KYTH
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download KYTH Pro Report PDF
Pro Strategies Featuring KYTH
Did KYTHERA Biopharmaceuticals make it into our Pro Portfolio Strategies?
KYTH Profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Major
Other KYTH Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| KYTH | 21.32 | -0.80 | -3.62% | 391.96M |
